EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or Obesity

Het Tushar Jani, Helisse Levine, Abhiraj Patel, Richa Trivedi, Xitij Dineshkumar Patel

Rambam Maimonides Medical Journal · 26.10.2026 · 17 (4) · e0024

DOI: 10.5041/rmmj.10585 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Rambam Maimonides Medical Journal, online erschienen am 26.10.2026. Verfasst von Het Tushar Jani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Master of Public Health Program, Long Island University, Brooklyn, New York, USA. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Neuropsychiatric safety concerns about glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and tirzepatide prompted regulatory review by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). We synthesized the contemporary evidence in adults with type 2 diabetes mellitus or obesity, emphasizing study design, risk of bias, and the distinction between signal detection and causal inference.

Methods

The PubMed/MEDLINE, Embase, Web of Science, and Scopus databases were searched without a lower date limit through March 15, 2026 (English, adults ≥18 years). The review was reported with reference to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020, and the PRISMA-S and PRISMA-Harms extensions. Evidence was grouped into prespecified categories: randomized syntheses, comparative observational studies and target-trial emulations, outlier non-active-comparator studies, pharmacovigilance analyses, and regulatory reviews. Risk of bias was appraised with the Cochrane Risk of Bias 2 tool and with Risk of Bias in Non-randomised Studies of Interventions; certainty was summarized using Grading of Recommendations Assessment, Development and Evaluation.

Results

Twenty studies and two regulatory reviews met the inclusion criteria. Randomized evidence, including two large 2025 meta-analyses and post hoc pooled analyses of semaglutide and tirzepatide, showed no increased risk of suicidality, depression, or anxiety, though psychiatric exclusion criteria limited generalizability. Active-comparator cohorts from the United States, Scandinavia, and the United Kingdom likewise showed no clear increase after confounding control. Passive-comparator and disproportionality analyses generated signals but could not separate drug effects from baseline psychiatric risk, obesity-related distress, or reporting bias. The EMA and FDA conclusions do not support a causal class-wide association between GLP-1 RAs and suicidal ideation or behavior.

Conclusions

Evidence does not support a clinically meaningful increase in neuropsychiatric harm with GLP-1 RAs or tirzepatide in the populations studied. Surveillance remains warranted for patients with substantial psychiatric morbidity, for obesity-only populations, and for long-term rare outcomes.

Autor:innen und Institutionen

  • Master of Public Health Program, Long Island University, Brooklyn, New York, USA.
  • Frank H. Netter MD School of Medicine, Quinnipiac University, North Haven, Connecticut, USA.
  • St. Vincent's Medical Center, Hartford HealthCare, Bridgeport, Connecticut, USA.

Zitieren

APA

Jani, H. T., Levine, H., Patel, A., Trivedi, R., & Patel, X. D. (2026). Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or Obesity. Rambam Maimonides Medical Journal, 17(4), e0024. https://doi.org/10.5041/rmmj.10585

Vancouver

Jani HT, Levine H, Patel A, Trivedi R, Patel XD. Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or Obesity. Rambam Maimonides Medical Journal. 2026;17(4):e0024. doi:10.5041/rmmj.10585

BibTeX
@article{Jani2026,
  author = {Jani, Het Tushar and Levine, Helisse and Patel, Abhiraj and Trivedi, Richa and Patel, Xitij Dineshkumar},
  title = {Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or Obesity},
  journal = {Rambam Maimonides Medical Journal},
  year = {2026},
  volume = {17},
  number = {4},
  pages = {e0024},
  doi = {10.5041/rmmj.10585}
}
Kostenlos starten →